NL-OMON21439招募中不适用
Open-label, randomized, multi-center study investigating Cetuximab, in combination with concurrent chemo- / radiotherapy in locally advanced non-small cell lung carcinoma.
KI-AV0 个研究点目标入组 110 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 110
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. >= 18 years of age;
- •2. Histologically or cytologically confirmed diagnosis of NSCLC;
排除标准
- •1. Concurrent active malignancy other than localized, non-melanoma skin cancer or carcinoma-in-situ of the cervix (unless definitive treatment was completed 5 years or more before study entry and the patient has remained disease free);
研究者
相似试验
招募中
不适用
A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of obinutuzumab (Gazyvaro) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimensChronic Lymphocytic Leukemia (CLL)NL-OMON23205HOVON data center70
进行中（未招募）
2 期
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma MultiformeGlioblastoma Multiforme, AdultNCT04762069CNS Pharmaceuticals, Inc.252
招募中
2 期
TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal CancerColorectal CancerNCT06293014Henan Cancer Hospital224
撤回
4 期
A Multicenter Study to Compare the Efficacy and Safety of the Combination of Etanercept and Methotrexate in Treatment of Rheumatoid ArthritisRheumatoid ArthritisNCT00783536Wyeth is now a wholly owned subsidiary of Pfizer
尚未招募
2 期
Open-label, randomised, multi-center study investigating Cetuximab, in combination with concurrent chemo- / radiotherapy in locally advanced non-small cell lung carcinomaLung cancerNL-OMON32353Antoni van Leeuwenhoek Ziekenhuis112